Information Provided By:
Fly News Breaks for November 15, 2017
KPTI
Nov 15, 2017 | 07:04 EDT
H.C. Wainwright analyst Edward White assumed coverage of Karyopharm Therapeutics with a Buy rating and $23 price target. The analyst believes the company's lead candidate selinexor has potential across several cancer types, including both hematological and solid tumor malignancies as part of combination therapy.
News For KPTI From the Last 2 Days
There are no results for your query KPTI